Sarepta Dives After FDA Rejects Its Newest Muscular Dystrophy Drug Sarepta Therapeutics (SRPT) toppled late Monday after the Food and Drug Administration rejected the biotech company’s latest Duchenne muscular dystrophy drug. In after-hours trading on the stock market today, Sarepta stock tumbled 12% to 106. That signals a move to…